Danilo Verge - Zealand Pharma Head Affairs
| ZEAL Stock | DKK 726.50 29.50 4.23% |
Insider
Danilo Verge is Head Affairs of Zealand Pharma AS
| Phone | 45 88 77 36 00 |
| Web | https://www.zealandpharma.com |
Zealand Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sren Jelert | ALK Abell AS | 50 | |
| Thomas Schmidt | Ambu AS | 52 | |
| Annette Terndrup | FLSmidth Co | 54 | |
| Mette MEng | FLSmidth Co | 56 | |
| Bassel Rifai | Ambu AS | N/A | |
| Paolo Paoletti | Genmab AS | 68 | |
| Henrik Ankjr | Ambu AS | N/A | |
| Marisol Peron | Genmab AS | N/A | |
| Henrik MSc | Bavarian Nordic | 58 | |
| Britt Jensen | Ambu AS | 50 | |
| Cori Petersen | FLSmidth Co | 54 | |
| Rolf Srensen | Bavarian Nordic | N/A | |
| Birgitte MSc | Genmab AS | 62 | |
| Judith MD | Genmab AS | 65 | |
| Paul MSc | Bavarian Nordic | 56 | |
| Michael Bauer | Genmab AS | 55 | |
| Judith Klimovsky | Genmab AS | 63 | |
| Anthony Pagano | Genmab AS | 45 | |
| Daniel Bruno | Genmab AS | 39 | |
| Birgitte Stephensen | Genmab AS | 59 | |
| Pr MD | ALK Abell AS | N/A | |
Management Performance
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 |
Zealand Pharma AS Leadership Team
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henriette Wennicke, Chief Officer | ||
| Lani Morvan, Investor Officer | ||
| Adam MD, Pres CEO | ||
| Hanne Bak, RD Director | ||
| Mads Kronborg, Head Communication | ||
| Ravinder Chahil, Sr Counsel | ||
| Christina Bredal, VP Organization | ||
| Danilo Verge, Head Affairs | ||
| Ivan Moller, Chief Officer | ||
| Jens MD, Head Pharmacology |
Zealand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X |
Pair Trading with Zealand Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zealand Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zealand Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Zealand Stock
| 0.73 | NOVO-B | Novo Nordisk AS | PairCorr |
| 0.71 | GMAB | Genmab AS | PairCorr |
| 0.7 | ALK-B | ALK Abell AS | PairCorr |
| 0.71 | BAVA | Bavarian Nordic | PairCorr |
Moving against Zealand Stock
The ability to find closely correlated positions to Zealand Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zealand Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zealand Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zealand Pharma AS to buy it.
The correlation of Zealand Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zealand Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zealand Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zealand Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.